Space LiinTech Signs Agreement with U.S. Starlab
Building an AI-Based Platform for Drug Research and Production After ISS

A domestic space medicine company has secured a next-generation research base aboard a commercial space station for the first time, in preparation for the retirement of the International Space Station (ISS). The company plans to expand new drug research and pharmaceutical production, which utilize microgravity environments, to private commercial space stations, with the goal of capturing a leading position in the global space medicine market.


On July 14, Space LiinTech announced that it has signed an agreement with U.S. commercial space station developer Starlab Space LLC to secure research module space, and that it will establish an AI-based space medicine research and manufacturing platform on the Starlab station in the future.

Image of the automated research module BEE-PC1, which completed demonstration on the ISS in 2025. It was created with an interior aerial view of Star Lab as the background. Provided by Space LiinTech.

Image of the automated research module BEE-PC1, which completed demonstration on the ISS in 2025. It was created with an interior aerial view of Star Lab as the background. Provided by Space LiinTech.

View original image

This agreement marks the first time a South Korean private company has secured research space on a commercial space station. Based on this, the company aims to expand its capabilities in protein pharmaceutical research and manufacturing on private low-Earth orbit space stations that will take over after 2030, following the ISS's retirement.


New drug development utilizing microgravity... Building a space medicine platform


Starlab is a next-generation commercial space station under development with the participation of Voyager Space, Airbus, Mitsubishi Corporation, MDA Space, and Palantir Technologies. Its goal is to provide low-Earth orbit research and manufacturing infrastructure led by the private sector after the ISS is retired.


Space LiinTech plans to advance protein crystallization research and pharmaceutical manufacturing technology using the microgravity environment available on Starlab. In microgravity, there is little convection or sedimentation due to gravity, increasing the likelihood of forming more uniform protein crystals than on Earth. This enables precise analysis of protein three-dimensional structures, thereby enhancing the efficiency of structure-based drug design and formulation development.


The company intends not only to conduct research but also to build a space medicine platform that handles pharmaceutical manufacturing on commercial space stations. By applying AI-based autonomous operation technology, they will develop systems that allow real-time monitoring of experiments and automated control of research processes, even in space environments.

Exterior photo of StarLab Commercial Space Station. Provided by StarLab Space

Exterior photo of StarLab Commercial Space Station. Provided by StarLab Space

View original image

Byungho Kim, Head of the Space Medicine Division at Space LiinTech, said, "The combination of microgravity and AI-based autonomous operation technology can advance the ways in which drug research is designed and monitored. This agreement marks the starting point for building a space medicine platform that connects Korean biopharmaceutical technology with next-generation commercial low-Earth orbit infrastructure."


Starlab CEO Marshall Smith commented, "AI has the potential to fundamentally transform how research is conducted in orbit. The combination of AI and microgravity research will accelerate new drug development and provide an opportunity to broaden international collaboration in the low-Earth orbit economy."



Space LiinTech plans to load the protein crystallization demonstrator 'BEE-1012' onto the fifth launch of the Nuri rocket in September this year, proceeding from ground validation to low-Earth orbit demonstration. In the future, the company intends to expand the platform's scope to commercial private space stations, creating an end-to-end space medicine platform from research and drug development to production.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing